key: cord-0825383-84wg6rfm
authors: Patel, Dillan; Borkar, Durga S.; Madhava, Malika; Obeid, Anthony; Mellen, Phoebe L.; Regillo, Carl D.; Garg, Sunir J.
title: Incidence of Management Changes at the Postoperative Day One Visit after Pars Plana Vitrectomy for Retinal Detachment
date: 2020-09-28
journal: Am J Ophthalmol
DOI: 10.1016/j.ajo.2020.09.034
sha: d91121159b7b52f4e44116916978b796a073699e
doc_id: 825383
cord_uid: 84wg6rfm

PURPOSE: To evaluate the incidence of unexpected management changes on the first day after pars plana vitrectomy for retinal detachment repair DESIGN: Retrospective cohort study PARTICIPANTS: All cases of pars plana vitrectomy (PPV) for rhegmatogenous or tractional retinal detachment with completed postoperative day one (POD1) and week one (POW1) visits were included. METHODS: The medical and billing records of a large academic private practice were electronically queried for all cases of PPV for retinal detachment performed between January 1, 2017 and December 31, 2017. The preoperative consultation, operative report, and POD1 and POW1 (postoperative days 5-14) visits were reviewed. MAIN OUTCOME MEASURES: Incidence of unexpected management changes (change in or extended positioning, additional procedure, change in drop regimen, or shortened interval follow-up) at the POD1 visit after uncomplicated PPV for retinal detachment. RESULTS: Overall, 418 surgeries from 364 eyes and 355 patients were included. Eleven cases (2.6%) had an intraocular pressure (IOP) over 30 mmHg at POD1. IOP lowering drops were prescribed for 30 cases (7.2%). Silicone oil tamponade was positively associated with high IOP at POD1 (RR = 3.23, 95% CI 0.96 –10.84, P = 0.06). No additional management changes were made besides treating elevated IOP. CONCLUSIONS: Management changes POD1 after vitrectomy for retinal detachment repair are relatively uncommon and were solely IOP related in this patient group. There may be flexibility regarding the type of POD1 encounter necessary, including an IOP check with an ophthalmic technician or non-retinal eye care provider. Larger, prospective studies are needed to better determine the most efficient follow-up routine.

Currently, the typical postoperative visit schedule following routine pars plana 3 vitrectomy for rhegmatogenous retinal detachment is an examination at postoperative 4 day 1 (POD1), week 1 (POW1), month 1 (POM1), and month 3 (POM3). 1 Complications 5 screened for at the POD1 visit include elevated intraocular pressure (IOP), 6 endophthalmitis, wound leaks, hypotony, choroidal detachments, corneal 7 decompensation, and failure of retinal reattachment. 2,3 All of these adverse effects could 8

have serious long-term consequences on vision if left untreated. However, anecdotal 9

evidence and prior smaller studies suggest that the primary problem detected at the 10 POD1 visit is an elevation in IOP, especially in eyes treated with silicone oil and gas 11

tamponade. 2 12

Recently, the efficiency of the POD1 visit for routine pars plana vitrectomy has 13 been called into question. [2] [3] [4] Due to advancements in surgical techniques, such as 14 smaller gauge vitrectomy, adverse events following pars plana vitrectomy has 15

decreased. 2,4 For example, elevated IOP on POD1 after 20-gauge vitrectomy was seen 16 in 14.9% of patients. 5 However, elevated IOP on POD1 from a 23-gauge, 25-gauge, or 17

27-gauge vitrectomy occurred in only 3.9% of patients. 1 Hypotony is less common and 18

was reported in six out of three hundred ten eyes evaluated on POD1 (1.9%). 1 If 19 present, hypotony is typically transient and self-resolving. Additionally, postoperative 20 endophthalmitis is rare, particularly in an asymptomatic patient on postoperative day 21 one. [6] [7] [8] [9] The incidence of any postoperative adverse events at the POD1 timepoint has 22

been reported as 0.5% with these newer, routinely utilized surgical platforms. 4 23

Streamlining postoperative care following pars plana vitrectomy may ease the 24 burden of care for patients, particularly those who need to travel long distances for 25 office visits. 2 For each case, the preoperative consultation closest to the date of surgery, 3 operative report, postoperative day one visit, and postoperative week one 4 (postoperative days 4-14) visit. Cases were excluded if a scleral buckle alone was 5 performed, significant intraoperative complications were noted, or the case was 6 performed in conjunction with cataract extraction and intraocular lens insertion. 7

The preoperative consultation was reviewed for baseline demographic 8 characteristics, as well as clinical characteristics including history of prior ocular 9 surgeries, ocular hypertension or glaucoma, and all ophthalmic medications. The 10 operative report was then reviewed to note gauge used, complications, peripheral 11

pathology, performance of a scleral buckle, and tamponade agent. The postoperative 12 day one evaluation was evaluated for examination information. A patient was 13 considered to have an unexpected management change at the POD1 visit if there was 14

(1) a change in the standard steroid or antibiotic drop regimen typically prescribed by 15 the provider, (2) an addition of an IOP lowering drop and/or IOP greater than or equal to 16 30 mm Hg, (3) a change in the positioning instructions compared to what was initially 17

prescribed, and (4) a shortened follow up interval specifically noted in the plan.

The charts of all patients who were noted to have a postoperative day one 19 management change were reviewed again by one of the other study investigators (DSB, 20 DP) to confirm that a management change had occurred at the postoperative day one 21

visit. STATA 12.0 (StataCorp, College Station, TX) was used for all descriptive statistics 22

provided in this study.

Results

Overall, 418 surgeries from 364 eyes and 355 patients were included in this 27 study. No eyes were excluded due to significant intraoperative complications. 54 eyes 28

were included more than once due to multiple vitrectomies within the study period. 205 29 of these patients were female (57.7%), and the average age was 60.7 ± 13.2 years 30

( 

The examining physician made a management change for 30 of 418 cases (7.2 1 %), all of which were for elevated IOP, including the 11 eyes with an IOP > 30 mm Hg. 2

For these 11 eyes, all changes involved the addition of an IOP lowering drop. One 3 patient who had an IOP of 51 also required a vitreous tap to normalize the IOP to 25 on 4 POD1. 5

Eight of these 11 eyes had normalization of IOP at the POW1 visit. One eye had 6

an additional ocular anti-hypertensive drop added at POW1 with normalization of 7 pressures by postoperative month 3. One eye needed to return to the operating room at 8 the POW1 for silicone oil removal and anterior chamber washout due to IOP of 62. One 9

eye was lost to follow-up after the POW1 period. 10

For the remaining 19 eyes with an IOP between 22 and 30 mm Hg, the addition 11

of an IOP lowering drop was the only management change. J o u r n a l P r e -p r o o f not have been accurately diagnosed with glaucoma prior to their surgery, which can 1 affect the interpretation of postoperative results. In our study, the number of cases with 2 elevated IOP after PPV was 2.2% at POD1 without a known preexisting history of 3 glaucoma or ocular hypertension. If streamlined postoperative visits were utilized, it 4 could be focused on patients without a history of preexisting glaucoma or ocular 5 hypertension as well as those without silicone oil tamponade. Patients with a history of 6 moderate to severe glaucoma should be screened for IOP elevation POD1 given the 7 potential for irreversible vision loss, even with mildly elevated IOP. 8

In our study, the incidence of unexpected management changes at the POD1 9

visit after routine pars plana vitrectomy for retinal detachment was 7.2%. These 10 changes in management were all related to elevated IOP. A prospective study of 25 11 patients showed that IOP increased after simple PPV and peaked at 2 hours. However, 12

by the 24-hour time mark, all but one patient had levels return to normal levels. 17 

Similarly, another study examining 138 patients and 102 eyes looked at the rate of IOP 14

after PPV and changes in management. The rate of IOP elevation on POD1 was 9.8% 15 and transient, returning to baseline after an average of 11.2 days. 18 However, only 1.4% 16 of patients in that study required significant changes to their management for IOP 17

control. 18 Some eyes will present with a benign rise in IOP following vitrectomy that will 18 normalize early in the postoperative course; few cases in our study required additional 19 management. However, it is notable that we do not have long-term follow up data on 20 these patients and there is a long-term risk of developing open-angle glaucoma from 21 vitrectomy itself. 19 22

The tamponade used has also been studied with respect to IOP elevation.

Silicone oil has been found to have the highest rates of long-term elevation in IOP when 24 compared to C3F8 and SF6. 11,20 Silicone oil can damage the aqueous outflow tract, 25

leading to persistent ocular hypertension. In our study, there was an association 26

between elevated IOP at POD1 and silicone oil tamponade; however, it did not reach 27 statistical significance. These early IOP increases could be due to silicone oil affecting 28 the inflammatory response, pupillary block, or migration of the oil into the anterior 29 chamber. 14 The other tamponade agents, SF6 and C3F8, did not have a significant 30 association with elevated IOP. A larger study could help further clarify this association. If 31 streamlined office visits were considered at the POD1 timepoint, this initiative could be 32 focused on patients who do not have silicone oil tamponade. 33

Another potentially serious complication of vitrectomy is endophthalmitis. There 34

were no cases of endophthalmitis in this study; however, rates are typically low so a 35 study of this size, while large, would not be expected to have any endophthalmitis 36 cases. A recent meta-analysis reported 0.05% of patients were diagnosed with 37 endophthalmitis after vitrectomy. 21 A concern could be patients presenting with 38 asymptomatic endophthalmitis. However, in the Endophthalmitis Vitrectomy Study, 39

98.8% of patients who developed endophthalmitis after cataract surgery had a 40 presenting symptom. 22 This includes decreased vision, red eye, or eye pain and 41

typically occurs within one week postoperatively. 22,23 Additionally, endophthalmitis is 42 very rare on POD1, especially in an asymptomatic patient, and clinically presents on 43 average 3.6 days after PPV. 6-9 44 A recent study that included 231 patients showed the effects of changing from a 45 standard postoperative day one visit within 24 hours to having the first postoperative 46 visit after at least 72 hours. 24 Only 2.0% of patients required management changes that 1

were predominantly IOP related. 24 There were no cases of endophthalmitis, and 2 tamponade was not predictive of postoperative complications. 24 The results align with 3

the findings in the current study. 4

There are some limitations to this study. This study was conducted in a large 5 academic referral-based private practice and may have limited generalizability to the 6 general population. A number of eyes in our series had retinal detachment repair 7 elsewhere and were referred to our center for additional repair which accounts for a 8 greater use of silicone oil than would be reported in a series of primary retinal 9 detachment repair. This was a retrospective study and thus standardization of 10 screenings and follow-up visits was not achieved. Also, the relatively small number of 11 patients in each subgroup based on baseline, preoperative, intraoperative, and 12

postoperative characteristics made subgroup analysis difficult to conduct. While not 13 routine, some sclerotomies required sutures for closure but there was inconsistent 14 description in the operative reports regarding which sclerotomies may have been 15

sutured. Eyes with a history of elevated IOP or glaucoma may have had less gas or oil 16

instilled compared to those without such a history. Lastly, this study did not investigate 17

the stages of glaucoma in glaucomatous eyes to account for potential differences in 18 length of periods tolerable to high IOP.

This study has several strengths. Over four hundred eyes in this study were 20

analyzed with respect to their POD1 outcomes. This cohort is larger than those 21

analyzed in similar studies, allowing for better generalizability and confidence in creating 22 some flexibility from the standard early postoperative visit schedule. This paper also 23 focused only on retinal detachment repaired with pars plana vitrectomy which helps to 24 limit confounding variables. Lastly, the data from this study was collected from many 25 surgeons at this large academic private practice. This helps increase generalizability 26 compared to studying cases from a single surgeon.

In summary, this study shows that management changes at the POD1 visit after 28 uncomplicated vitrectomy-based retinal detachment repair without concomitant cataract 29 extraction for patients are relatively uncommon with the main issue at the POD1 visit 30 being related to elevated IOP. Vitrectomy surgeries have become safer with 31 advancements in technology, leading to fewer postoperative complications. Our results 32

suggest that the type of the postoperative encounters may not always require a full 33 ophthalmic examination performed on POD1. Other considerations could be to schedule 34 a phone interview with a technician to screen for severe pain or discomfort, a telehealth 35 visit with their physician to review postoperative instructions, or an office visit with an 36 ophthalmic technician or local eye care provider for an IOP check. 2 The office visit with 37 an ophthalmic technician or other eye care provider would still allow for postoperative 38

instructions to be reviewed and allow patients to ask questions they may have regarding 39 their care. This visit could act as a screening tool for practices to determine which 40 patients need additional physician follow-up or may need changes in management.

These steps could increase practice efficiency, ease patient burdens, and help with 42 social distancing in select cases. Further studies should be conducted to explore these 43 potential alternatives. J o u r n a l P r e -p r o o f In 2 cases, patients were not receiving IOP lowering medications J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

Intraocular pressure elevation after simple pars plana vitrectomy

Rate of Elevated Intraocular Pressure Post Primary 4 Vitrectomy Surgery

Jackson lecture: open angle glaucoma after vitrectomy

Incidence and 8 Risk Factors of Ocular Hypertension following Pars Plana Vitrectomy and 9 Silicone Oil Injection

Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate 14 vitrectomy and of intravenous antibiotics for the treatment of postoperative 15 bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group

Short-and Long-Term Outcomes of Vitreoretinal Surgeries 19 with Deferred First Postoperative Visits at Day 3 or Later